Semaglutide Popularity: Serious Rare Adverse Effects Are Emerging
December 11, 2023 – In June of 2021, the American Food and Drug Administration (FDA) approved the drug semaglutide for chronic weight management under the brand name Wegovy, ushering in a new era of obesity treatment. Since then, demand for …
Semaglutide Popularity: Serious Rare Adverse Effects Are Emerging Read more »